The dichotomous relationship pro- and anti-tumor effects of IRE1α and ATF6 warrant scrutiny to ensure that biomarker-driven strategies are advanced judiciously in specific cancer populations such that cancer pro-survival pathways are not triggered accidentally. The gene discussed is ATF6; the disease is cancer.